共 218 条
[1]
Kamangar F(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-2150
[2]
Dores GM(1993)modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric-cancer Cancer 72 37-41
[3]
Anderson WF(1995)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591
[4]
Murad AM(1980)5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer Ann Intern Med 93 533-536
[5]
Santiago FF(1994)A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) Ann Oncol 5 609-616
[6]
Petroianu A(2003)Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54-59
[7]
Rocha PRS(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncology 10 1063-1069
[8]
Rodrigues MAG(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncology 9 215-221
[9]
Rausch M(1996)Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293 Med Oncol 13 87-93
[10]
Pyrhonen S(2006)Docetaxel in the treatment of gastric cancer Future Oncol 2 603-620